Of the 32 patients who received an injection of XC001, 81% had an improvement in angina class 6 months after the procedure.
The injection — an adenoviral 5 vector that delivers three isoforms of vascular endothelial growth factor (VEGF) to the heart — is delivered through a minithoracotomy.
In the EXACT study, no severe adverse events were attributed to the treatment itself. There were 20 severe adverse events in 13 patients, but they were due to surgery and were within expectations.
The study measured 12-month changes in four markers of cardiac function in treated patients, which showed that:
https://www.medscape.com/viewarticle/angina-gene-therapy-coaxes-heart-vessel-growth-2024a10008mx